Biomedical Engineering Reference
In-Depth Information
11. Li S, Schmitz KR, Jeffrey PD,
Structural basis for inhibition of the
epidermal growth factor receptor by cetuximab.
et al.
Cancer Cell
7, 201-
311 (2005).
12.
Ciardiello F, Tortora G. EGFR Antagonists in Cancer Treatment. NEJM
358, 1160-1174 (2008)
.
13. Giaccone G, Herbst RS, Manegold C,
Gefitinib in combination with
gemcitabine and cisplatin in advanced non-small cell lung cancer: a
phase III trial—INTACT1.
et al.
22, 777-784 (2004).
14. Herbst RS, Giaccone G, Shiller JH,
JCO
Gefitinib in combination with
paclitaxel and carboplatin in advanced non-small-cell lung cancer: a
phase III trial—INTACT 2.
et al.
22, 785-794 (2004).
15. Herbst RS, Prager D, Hermann R,
JCO
TRIBUTE: a phase III trial of
erlotinib hydrochloride (OSI-774) combined with carboplatin and
paclitaxel chemotherapy in advanced non-small-cell cancer.
et al.
JCO
23,
5892-5899 (2005).
16. Gatzemeier U, Pluzanska A, Szczesna A,
Phase III study of erlotinib
in combination with cisplatin and gemcitabine in advanced non-small-
cell lung cancer: the Tarceva Lung Cancer Investigation Trial.
et al.
JCO
25,
1545-1552 (2007).
18. Shepherd FA, Rodrigues Pereira J, Ciuleanu T,
et al.
Erlotinib in
previously treated non-small-cell lung cancer.
NEJM
353, 123-32.
19. Kim ES, Hirsh V, Mok T,
Gefitinib versus docetaxel in previously
treated non-small-cell lung cancer (INTEREST): a randomised phase
III trial.
et al.
Lancet
372, 1809-1818 (2008).
20. Mok TS,
Gefitinib or carboplatin-paclitaxel in pulmonary
adenocarcinoma.
et al.
361, 947-957 (2009).
21. Pirker R, Pereira JR, Szczesna A,
NEJM
Cetuximab plus chemotherapy
in patients with advanced non-small-cell lung cancer (FLEX): an open-
label randomised phase III trial.
et al.
Lancet
373, 1525-1531 (2009).
22. Lynch TJ, Patel T, Dreisbach L,
Cetuximab and first-line taxane/
carboplatin chemotherapy in advanced non-small-cell lung cancer:
results of the randomized multicenter phase III trial BMS099.
et al.
JCO
28,
911-917 (2010).
23. Kosaka T, Yatabe Y, Endoh H,
Mutations of the epidermal growth
factor receptor gene in lung cancer: biological and clinical implications.
Cancer Res
et al.
64, 8919-8923 (2004).
24. Gazdar AF. Activating and resistance mutations of EGFR in non-small-
cell lung cancer: role in clinical response to EGFR tyrosine kinase
inhibitors.
Oncogene
28, s24-s31 (2009).
